-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Hold on Theravance Biopharma, Raises Price Target to $15

Benzinga·03/23/2026 14:56:24
Listen to the news
TD Cowen analyst Marc Frahm maintains Theravance Biopharma (NASDAQ:TBPH) with a Hold and raises the price target from $13 to $15.